BG107157A - Sustained release beadlets containing stavudine - Google Patents

Sustained release beadlets containing stavudine

Info

Publication number: BG107157A
Authority: BG; Bulgaria
Prior art keywords: beadlets; stavudine; extrusion; coated; magnesium stearate
Prior art date: 2000-03-30

Application number

BG107157A

Other languages

Bulgarian (bg)

English (en)

Inventor

Robert Abramowitz

DONOGHUE Denise O'

Nemichand JAIN

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-30

Filing date

2002-09-30

Publication date

2003-06-30

2002-09-30 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2003-06-30 Publication of BG107157A publication Critical patent/BG107157A/xx

Links

XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 title abstract 6
229960001203 stavudine Drugs 0.000 title abstract 6
238000013268 sustained release Methods 0.000 title 1
239000012730 sustained-release form Substances 0.000 title 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
239000011248 coating agent Substances 0.000 abstract 2
238000000576 coating method Methods 0.000 abstract 2
239000007903 gelatin capsule Substances 0.000 abstract 2
235000019359 magnesium stearate Nutrition 0.000 abstract 2
238000005563 spheronization Methods 0.000 abstract 2
206010038997 Retroviral infections Diseases 0.000 abstract 1
230000036765 blood level Effects 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000007062 hydrolysis Effects 0.000 abstract 1
238000006460 hydrolysis reaction Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

BG107157A 2000-03-30 2002-09-30 Sustained release beadlets containing stavudine BG107157A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19358800P	2000-03-30	2000-03-30
PCT/US2001/010078 WO2001074329A2 (en)	2000-03-30	2001-03-29	Sustained release beadlets containing stavudine

Publications (1)

Publication Number	Publication Date
BG107157A true BG107157A (en)	2003-06-30

Family

ID=22714247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107157A BG107157A (en)	2000-03-30	2002-09-30	Sustained release beadlets containing stavudine

Country Status (26)

Country	Link
US (1)	US7135465B2 (lt)
EP (1)	EP1267879A2 (lt)
JP (1)	JP2003528905A (lt)
KR (1)	KR20030011805A (lt)
CN (1)	CN1187052C (lt)
AR (1)	AR027748A1 (lt)
AU (1)	AU2001249591A1 (lt)
BG (1)	BG107157A (lt)
BR (1)	BR0109602A (lt)
CA (1)	CA2404687A1 (lt)
CZ (1)	CZ20023003A3 (lt)
EE (1)	EE200200564A (lt)
GE (1)	GEP20043285B (lt)
HU (1)	HUP0302631A2 (lt)
IL (1)	IL151475A0 (lt)
LT (1)	LT5045B (lt)
LV (1)	LV12939B (lt)
MX (1)	MXPA02009534A (lt)
NO (1)	NO20024645D0 (lt)
NZ (1)	NZ522250A (lt)
PE (1)	PE20011179A1 (lt)
PL (1)	PL366089A1 (lt)
RU (1)	RU2239435C2 (lt)
SK (1)	SK12822002A3 (lt)
WO (1)	WO2001074329A2 (lt)
ZA (1)	ZA200207760B (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
PL373148A1 (en) *	2002-06-27	2005-08-22	Cilag Ag	Spherical pellet formulations
EP2112920B1 (en)	2003-06-26	2018-07-25	Intellipharmaceutics Corp.	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en)	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US20060024361A1 (en) *	2004-07-28	2006-02-02	Isa Odidi	Disintegrant assisted controlled release technology
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) *	2004-11-24	2009-10-14	东北制药总厂	司他夫定缓释片剂
TWI457136B (zh)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
EA013474B1 (ru) *	2005-06-16	2010-04-30	Форест Лэборэтериз, Инк.	Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
KR20080053317A (ko) *	2005-08-31	2008-06-12	씨아이피엘에이 엘티디.	라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물
GB0525461D0 (en)	2005-12-15	2006-01-25	Archimedes Dev Ltd	Pharmaceutical compositions
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2636436C (en)	2006-01-20	2014-04-01	Tibotec Pharmaceuticals Ltd.	Long term treatment of hiv- infection with tmc278
EP2010162A4 (en) *	2006-04-03	2013-01-09	Isa Odidi	COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
WO2007112581A1 (en)	2006-04-03	2007-10-11	Isa Odidi	Controlled release delivery device comprising an organosol coat
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CN102319181B (zh) *	2011-09-08	2014-07-16	广东大华农动物保健品股份有限公司	一种微囊型动物药品的包被工艺
US20140271893A1 (en) *	2013-03-15	2014-09-18	Mcneil-Ppc, Inc.	Coated phenylephrine particles and use thereof in pharmaceutical formulations
CN106488778A (zh) *	2014-07-17	2017-03-08	陶氏环球技术有限责任公司	乙基纤维素分散体和薄膜
CN105511174A (zh) *	2016-01-05	2016-04-20	深圳市华星光电技术有限公司	液晶显示面板和显示装置

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4671963A (en)	1983-10-28	1987-06-09	Germino Felix J	Stearate treated food products
US4670270A (en)	1984-05-07	1987-06-02	Germino Felix J	Stearate treated food products
US4940556A (en)	1986-01-30	1990-07-10	Syntex (U.S.A.) Inc.	Method of preparing long acting formulation
US4978655A (en) *	1986-12-17	1990-12-18	Yale University	Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
GB8707421D0 (en) *	1987-03-27	1987-04-29	Wellcome Found	Pharmaceutical formulations
EP0619731B1 (en)	1991-12-30	2000-10-04	Fmc Corporation	Microcrystalline cellulose spheronization composition
US5472711A (en)	1992-07-30	1995-12-05	Edward Mendell Co., Inc.	Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en)	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi)	1992-10-09	1998-04-15	Eeva Kristoffersson	Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) *	1992-11-02	1999-02-09	Alza Corporation	Method of therapy comprising an osmotic caplet
GB9403449D0 (en)	1994-02-23	1994-04-13	Wellcome Found	Therapeutic benzonitriles
ES2139195T3 (es)	1994-03-07	2000-02-01	Vertex Pharma	Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
GB9417249D0 (en) *	1994-08-26	1994-10-19	Wellcome Found	A novel salt
EP0814806A1 (en)	1995-02-23	1998-01-07	Janssen Pharmaceutica N.V.	Use of fused benzothiazoles as neuroprotectants
US6177460B1 (en)	1995-04-12	2001-01-23	The Procter & Gamble Company	Method of treatment for cancer or viral infections
US5691372A (en)	1995-04-19	1997-11-25	Vertex Pharmaceuticals Incorporated	Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
EA001957B1 (ru)	1995-12-15	2001-10-22	Вироден Фармасьютикал Холдингс (Проприетэри) Лимитед	КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДа
SE9600072D0 (sv)	1996-01-08	1996-01-08	Astra Ab	New oral formulation of two active ingredients II
US5883252A (en)	1996-01-26	1999-03-16	Vertex Pharmaceuticals Incorporated	Aspartyl protease inhibitors
US5766623A (en)	1996-03-25	1998-06-16	State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University	Compactable self-sealing drug delivery agents
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
US5780055A (en)	1996-09-06	1998-07-14	University Of Maryland, Baltimore	Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en)	1996-09-24	1999-05-18	Abbott Laboratories	Retroviral protease inhibiting compounds
AU721653B2 (en)	1996-10-25	2000-07-13	Supernus Pharmaceuticals, Inc.	Soluble form osmotic dose delivery system
US5962462A (en)	1996-12-13	1999-10-05	Merck & Co., Inc.	Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en)	1996-12-20	1999-07-06	Merck & Co., Inc.	Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en)	1997-01-21	2000-09-26	Merck & Co., Inc.	3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en)	1997-07-25	2000-10-24	Merck & Co., Inc.	Cyclic amine modulations of chemokine receptor activity
PT1003476E (pt)	1997-08-11	2005-05-31	Alza Corp	Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
US6166037A (en)	1997-08-28	2000-12-26	Merck & Co., Inc.	Pyrrolidine and piperidine modulators of chemokine receptor activity
ES2236943T3 (es) *	1997-09-19	2005-07-16	Shire Laboratories Inc.	Perlas de disolucion solida.
US5904937A (en)	1997-10-03	1999-05-18	Fmc Corporation	Taste masked pharmaceutical compositions
US6180634B1 (en)	1997-11-13	2001-01-30	Merck & Co., Inc.	Combination therapy for the treatment of AIDS
US6013644A (en)	1997-12-12	2000-01-11	Merck & Co., Inc.	Spiro-substituted azacycles as modulators of chemokine receptor activity
US6172061B1 (en)	1997-12-19	2001-01-09	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6140349A (en)	1998-02-02	2000-10-31	Merck & Co., Inc.	Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) *	1998-05-22	2006-10-17	Bristol-Myers Squibb Company	High drug load acid labile pharmaceutical composition
US6093743A (en)	1998-06-23	2000-07-25	Medinox Inc.	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
BR9911457A (pt)	1998-06-24	2001-12-11	Univ Emory	Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
WO2000057870A2 (en)	1999-03-31	2000-10-05	The Procter & Gamble Company	Viral treatment
US6136835A (en)	1999-05-17	2000-10-24	The Procter & Gamble Company	Methods of treatment for viral infections

2001
- 2001-03-29 BR BR0109602-8A patent/BR0109602A/pt not_active IP Right Cessation
- 2001-03-29 US US09/821,103 patent/US7135465B2/en not_active Expired - Lifetime
- 2001-03-29 AR ARP010101516A patent/AR027748A1/es unknown
- 2001-03-29 KR KR1020027012769A patent/KR20030011805A/ko not_active Withdrawn
- 2001-03-29 CN CNB018074405A patent/CN1187052C/zh not_active Expired - Fee Related
- 2001-03-29 EE EEP200200564A patent/EE200200564A/xx unknown
- 2001-03-29 CZ CZ20023003A patent/CZ20023003A3/cs unknown
- 2001-03-29 HU HU0302631A patent/HUP0302631A2/hu unknown
- 2001-03-29 IL IL15147501A patent/IL151475A0/xx unknown
- 2001-03-29 JP JP2001572074A patent/JP2003528905A/ja active Pending
- 2001-03-29 WO PCT/US2001/010078 patent/WO2001074329A2/en not_active Ceased
- 2001-03-29 SK SK1282-2002A patent/SK12822002A3/sk unknown
- 2001-03-29 RU RU2002126540/15A patent/RU2239435C2/ru not_active IP Right Cessation
- 2001-03-29 EP EP01922832A patent/EP1267879A2/en not_active Withdrawn
- 2001-03-29 AU AU2001249591A patent/AU2001249591A1/en not_active Abandoned
- 2001-03-29 MX MXPA02009534A patent/MXPA02009534A/es not_active Application Discontinuation
- 2001-03-29 GE GEAP20016630A patent/GEP20043285B/en unknown
- 2001-03-29 CA CA002404687A patent/CA2404687A1/en not_active Abandoned
- 2001-03-29 NZ NZ522250A patent/NZ522250A/en unknown
- 2001-03-29 PL PL01366089A patent/PL366089A1/xx not_active Application Discontinuation
- 2001-03-30 PE PE2001000297A patent/PE20011179A1/es not_active Application Discontinuation
2002
- 2002-09-06 LT LT2002099A patent/LT5045B/lt not_active IP Right Cessation
- 2002-09-26 ZA ZA200207760A patent/ZA200207760B/en unknown
- 2002-09-27 NO NO20024645A patent/NO20024645D0/no not_active Application Discontinuation
- 2002-09-30 BG BG107157A patent/BG107157A/xx unknown
- 2002-10-25 LV LVP-02-187A patent/LV12939B/en unknown

Also Published As

Publication number	Publication date
CZ20023003A3 (cs)	2002-11-13
AR027748A1 (es)	2003-04-09
RU2239435C2 (ru)	2004-11-10
SK12822002A3 (sk)	2003-02-04
WO2001074329A3 (en)	2002-05-10
GEP20043285B (en)	2004-07-26
RU2002126540A (ru)	2004-03-27
AU2001249591A1 (en)	2001-10-15
WO2001074329A2 (en)	2001-10-11
NO20024645L (no)	2002-09-27
CN1187052C (zh)	2005-02-02
NO20024645D0 (no)	2002-09-27
HUP0302631A2 (hu)	2003-11-28
LV12939B (en)	2003-04-20
MXPA02009534A (es)	2003-05-14
LT2002099A (lt)	2003-04-25
KR20030011805A (ko)	2003-02-11
BR0109602A (pt)	2004-06-29
PL366089A1 (en)	2005-01-24
EP1267879A2 (en)	2003-01-02
CN1420774A (zh)	2003-05-28
US7135465B2 (en)	2006-11-14
CA2404687A1 (en)	2001-10-11
IL151475A0 (en)	2003-04-10
EE200200564A (et)	2004-06-15
ZA200207760B (en)	2004-01-30
NZ522250A (en)	2004-09-24
JP2003528905A (ja)	2003-09-30
LT5045B (lt)	2003-08-25
PE20011179A1 (es)	2001-12-06
US20020002147A1 (en)	2002-01-03

Publication	Publication Date	Title
WO2001074329A3 (en)	2002-05-10	Sustained release beadlets containing stavudine
MXPA03006364A (es)	2003-10-06	TRATAMIENTO DE PERTURBACIONES DEL SUEnO.
NO20092274L (no)	2009-08-25	Ansamycinformuleringer og fremgangsmater for anvendelse derav
MY137348A (en)	2009-01-30	Highly selective norepinephrine reuptake inhibitors and methods of using the same
PL357144A1 (pl)	2004-07-12	Nowe postaci dawki podstawionego benzimidazolu oraz sposoby ich zastosowania
TNSN07145A1 (fr)	2008-11-21	Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0403935A (pt)	2005-08-09	Formas de dosagem de azitromicina com efeitos colaterais reduzidos
SG127714A1 (en)	2006-12-29	Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
BRPI0416602A (pt)	2007-01-30	promotores da apoptose de n-acilsulfonamida
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0212787A (pt)	2005-01-25	Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
ES2195344T3 (es)	2003-12-01	Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
BR0207316A (pt)	2004-02-10	Derivados de epotilona para o tratamento de tumores refratários
PL374443A1 (en)	2005-10-17	Novel pyrimidineamide derivatives and the use thereof
TW200624431A (en)	2006-07-16	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
PT1056454E (pt)	2003-08-29	Utilizacao de compostos macrolido para o tratamento do glaucoma
NO20050569L (no)	2005-11-22	Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
MY126117A (en)	2006-09-29	Pharmaceutical compositions
BR0310061A (pt)	2005-03-01	Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
IL147489A0 (en)	2002-08-14	Use of docetaxel for treating hepatocellular carcinoma
BR0114276A (pt)	2003-06-24	Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo
EP0870502A3 (en)	2001-04-04	Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
MX2008011769A (es)	2008-09-25	Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
BR0102940A (pt)	2002-03-05	Agente para o tratamento de doença de parkinson compreendendo um agente de melhora da função de astrócitos como ingrediente ativo
MXPA05010135A (es)	2005-11-16	Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.